OBJECTIVES: To describe the development and validation of an instrument to measure parents' attention deficit-hyperactivity disorder (ADHD) treatment preferences and goals. METHODS: Parents of children 6 to 12 years of age diagnosed with ADHD in the past 18 months were recruited from 8 primary care sites and an ADHD treatment center (autism excluded). A 16-item medication, 15-item behavior therapy preference scale and a 23-item goal scale, were developed after a review of the literature, 90 parent and clinician semistructured interviews, and input from parent advocates and professional experts were administered to parents. Parent cognitive interviews confirmed item readability, clarity, content, and response range. We conducted an exploratory factor analysis and assessed internal consistency and test-retest reliability and construct and concurrent validity. RESULTS: We recruited 237 parents (mean child age 8.1 years, 51% black, 59% from primary care, 61% of children medication naive). Factor analyses identified 4 medication preference subscales (treatment acceptability, feasibility, stigma, and adverse effects, Cronbach's α 0.74-0.87); 3 behavior therapy subscales (treatment acceptability, feasibility, and adverse effects, α 0.76-0.83); and 3 goal subscales (academic achievement, behavioral compliance, and interpersonal relationships, α 0.83-0.86). The most strongly endorsed goal was academic achievement. The scales demonstrated construct validity, concurrent validity (r = 0.3-0.6) compared with the Treatment Acceptability Questionnaire and Impairment Rating Scale and moderate to excellent test-retest reliability (intraclass coefficient = 0.7-0.9). CONCLUSIONS: We developed a valid and reliable instrument for measuring preferences and goals for ADHD treatment, which may help clinicians more easily comply with new national treatment guidelines for ADHD that emphasize shared decision making.
OBJECTIVES: To describe the development and validation of an instrument to measure parents' attention deficit-hyperactivity disorder (ADHD) treatment preferences and goals. METHODS: Parents of children 6 to 12 years of age diagnosed with ADHD in the past 18 months were recruited from 8 primary care sites and an ADHD treatment center (autism excluded). A 16-item medication, 15-item behavior therapy preference scale and a 23-item goal scale, were developed after a review of the literature, 90 parent and clinician semistructured interviews, and input from parent advocates and professional experts were administered to parents. Parent cognitive interviews confirmed item readability, clarity, content, and response range. We conducted an exploratory factor analysis and assessed internal consistency and test-retest reliability and construct and concurrent validity. RESULTS: We recruited 237 parents (mean child age 8.1 years, 51% black, 59% from primary care, 61% of children medication naive). Factor analyses identified 4 medication preference subscales (treatment acceptability, feasibility, stigma, and adverse effects, Cronbach's α 0.74-0.87); 3 behavior therapy subscales (treatment acceptability, feasibility, and adverse effects, α 0.76-0.83); and 3 goal subscales (academic achievement, behavioral compliance, and interpersonal relationships, α 0.83-0.86). The most strongly endorsed goal was academic achievement. The scales demonstrated construct validity, concurrent validity (r = 0.3-0.6) compared with the Treatment Acceptability Questionnaire and Impairment Rating Scale and moderate to excellent test-retest reliability (intraclass coefficient = 0.7-0.9). CONCLUSIONS: We developed a valid and reliable instrument for measuring preferences and goals for ADHD treatment, which may help clinicians more easily comply with new national treatment guidelines for ADHD that emphasize shared decision making.
Authors: Mark Wolraich; Lawrence Brown; Ronald T Brown; George DuPaul; Marian Earls; Heidi M Feldman; Theodore G Ganiats; Beth Kaplanek; Bruce Meyer; James Perrin; Karen Pierce; Michael Reiff; Martin T Stein; Susanna Visser Journal: Pediatrics Date: 2011-10-16 Impact factor: 7.124
Authors: José J Bauermeister; Glorisa Canino; Milagros Bravo; Rafael Ramírez; Peter S Jensen; Ligia Chavez; Alfonso Martínez-Taboas; Julio Ribera; Margarita Alegría; Pedro García Journal: J Am Acad Child Adolesc Psychiatry Date: 2003-07 Impact factor: 8.829
Authors: Nicole K Schatz; Gregory A Fabiano; Charles E Cunningham; Susan dosReis; Daniel A Waschbusch; Stephanie Jerome; Kellina Lupas; Karen L Morris Journal: Patient Date: 2015-12 Impact factor: 3.883
Authors: Jeremy J Michel; Stephanie Mayne; Robert W Grundmeier; James P Guevara; Nathan J Blum; Thomas J Power; Emily Coffin; Jeffrey M Miller; Alexander G Fiks Journal: Appl Clin Inform Date: 2018-12-19 Impact factor: 2.342
Authors: Jeritt G Thayer; Jeffrey M Miller; Alexander G Fiks; Linda Tague; Robert W Grundmeier Journal: Appl Clin Inform Date: 2019-04-03 Impact factor: 2.342
Authors: Thomas J Power; Jeremy Michel; Stephanie Mayne; Jeffrey Miller; Nathan J Blum; Robert W Grundmeier; James P Guevara; Alexander G Fiks Journal: Adv Sch Ment Health Promot Date: 2016-06-27
Authors: JoAnna K Leyenaar; Emily R O'Brien; Laurel K Leslie; Peter K Lindenauer; Rita M Mangione-Smith Journal: Pediatrics Date: 2016-12-02 Impact factor: 7.124
Authors: Lucy McGoron; Raymond Sturner; Barbara Howard; Tammy D Barry; Karen Seymour; Theodore S Tomeny; Tanya M Morrel; Brandi M Ellis; Danielle Marks Journal: Clin Pediatr (Phila) Date: 2014-09 Impact factor: 1.168